- Home
- Pathology Industry
- Biogen Idec Market and Forecasts, May 2013
Industries
- Pathology (16)
- Biopharmaceutical (15)
- Drug and Medication (8)
- Biotechnology (6)
- Pharmaceutical (6)
-
- Drug Discovery and Development (5)
- Biological Therapy (2)
- Generic Drug (2)
- Blood Supply, Tissue Banking and Transplantation (1)
- Business Outsourcing (1)
- Chemical and Material (1)
- Clean Vehicle (1)
- Energy & Environment (1)
- Genomics (1)
- Healthcare (1)
- Home and Office Goods (1)
- Investment Banking (1)
- Managed Care (1)
- Road Passenger Transport (1)
- Video Game (1)
Top countries
Publication dates
All regions
data types
- All
- Company Data (792)
- Country Data (86)
- Industry Data
Biogen Idec Market and Forecasts, May 2013
You might be interested in: clinical trial, multiple sclerosis, drug, more »
industry reports
» Download Public Reports
1-10 of 73 reports for Biogen Idec
Pharmaceutical in The United States : Innovation and Technology Trends
- Industry report
- June 2012
- 191 pages
- by Market Research Publisher
... Pierce, biogen idec S svp, global medical affairs since march 2012, joined biogen idec's hemophilia therapeutic area as a vice president and chief medical office in 2009. Prior to joining biogen idec, dr ...
- Industries: Pathology
- Countries: United States
U.S. Biotechnology Industry Analysis
- Industry report
- June 2011
- 78 pages
... Briefing19 tysabri is entrenched as last-line option for rrms, but continues to battle pml Tysabri, natilizumab (biogen idec/elan), was relaunched with significant restrictions in 2006 after being pulled ...
- Industries: Biotechnology
- Countries: United States
Biosimilar Business Brief (biosimilar, biopharmaceutical)
- Industry report
- May 2011
- 7 pages
... Choosing the best quality of proteins Requirements that are needed to be fulfilled before the cell-line process can be successful dr baisong mei, director, cell biology & process development, biogen ...
- Industries: Biopharmaceutical
Biosimilar Sector (biosimilar, biopharmaceutical, antibody) in The United States and The United Kingdom
- Industry report
- June 2011
- 4 pages
... The latest trends in the japanese biosimilar market and the impact of cultural aspects on the business dr mohamed oubihi, senior manager, regulatory affairs development, biogen idec, uk 14.30 Regulatory ...
- Industries: Biopharmaceutical
- Countries: United States, United Kingdom, World
Drug and Medication Sector
- Industry report
- April 2011
- 24 pages
... An independent company within biogen idec. Built out from 50 to 100 employees, adding employees in all r&d functions, commercial, finance, hr, it. 2 Ph 3 programs rfixfc and rfviifc 2009 head ...
- Industries: Drug and Medication
U.S. Drug Discovery Market : Innovation and Technology Trends
- Industry report
- October 2012
- 18 pages
... Multiple sclerosis (elan / biogen idec) Actemra which is used to treat rheumatoid arthritis (chugai / roche) 2 antibodies (originating from mrc labs) have been successfully humanized, re- vald ...
- Industries: Drug Discovery and Development
- Countries: United States
U.S. Biopharmaceutical Business Brief
- Industry report
- January 2012
- 2 pages
... Biopharmaceutical manufacturing, By j rg th mmes (vice president of global engineering and facilities at biogen idec) Improving access and affordability to biopharmaceuticals in the emerging markets through ...
- Industries: Biopharmaceutical
- Countries: United States, World
Pharmaceutical in The United States : Innovation and Technology Trends
- Industry report
- December 2011
- 32 pages
... Phase i completed . Novo nordisk fviia glyco-pegylation phase i novo nordisk fviii pegylated pre-clinical company strategy status biogen idec rfix-fc fusion, longer plasma half life phase ii/iii novo ...
- Industries: Pathology
- Countries: Europe, United States, World
Healthcare in The United States : Innovation and Technology Trends
- Industry report
- February 2011
- 9 pages
... Testing solutions4 Closed a $300 million biosimilars development joint venture with biogen idec to develop, manufacture and market biosimilars. Samsung will own 85% of the jv, while biogen will provide its ...
- Industries: Healthcare
- Countries: World, United States
Pharmaceutical Business in The United States and Canada
- Industry report
- June 2012
- 22 pages
... Biosciences Abcam Agilent technologies Amgen biogen idec Bristol-myers squibb Cephalon Celgene corporation Cellectis Cerus Covance biomarker center of excellence Cyprotex ...
- Industries: Pathology
- Countries: United States, Canada
» Purchase Premium Reports (From $ 95 - $ 11 400)
About 300 reports for Biogen Idec
Cancer Monoclonal Antibody Partnering Terms and Agreements
- $ 1 995
- Industry report
- May 2013
- by Currentpartnering
The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare ...
Reportlinker.com © Copyright 2013. All rights reserved.
